news

Macaques develop short-term immunity to SARS-CoV-2

Researchers experimenting on macaques reveal they were protected against reinfection up to a month after the initial exposure to SARS-CoV-2.

profile of a rhesus macaque, grey coated monkey with a pink face and ears

Six rhesus macaques infected with SARS-CoV-2, the virus causing the COVID-19 pandemic, were protected from reinfection for up to 28 days later.

Scientists from Peking Union Medical College, China, performed the experiment to find out if infection by SARS-CoV-2 would provide non-human primates with short-term immunity to the virus.

Six macaques were infected with SARS-CoV-2 in their trachea, all developed mild to moderate symptoms which they recovered from after two weeks. A month later, four of the six monkeys received another dose of SARS-CoV-2.

 

Reserve your FREE place

 


Are you looking to optimise antibody leads in your drug discovery? Register for this webinar to find out how!

30 July 2025 | 10:00 AM BST | FREE Webinar

Join this webinar to hear from Dr. Lei Guo as she shares how early insights into liability, PK, stability, and manufacturability can help you optimise antibody leads in early drug discovery – and mitigate downstream risks later in development.

What You’ll Learn:

  • How to assess key developability risks early
  • How in silico modelling and in vitro testing can be combined to predict CMC risks earlier in discovery stage
  • How micro-developability strategies are tailored for complex or novel formats

Don’t miss your chance to learn from real-world leaders

Register Now – It’s Free!

 

While the macaques had a brief rise in temperature following the second exposure, they displayed no signs of reinfection, said the study authors.

Frequent samples were taken by researchers throughout the experiment. These allowed the team to identify that the peak viral load was reached three days after the monkeys were infected.

According to the paper, the macaques showed a stronger immune response after the first infection, producing more neutralising antibodies which may have protected them against short-term reinfection.

The researchers caution that more experiments are needed to establish how long this immunity remains and that it is still unclear how it will last in humans – the world will need to wait months or even years to know if the millions of people infected during the COVID-19 pandemic are protected from reinfection.

The paper was published in Science.

Related conditions
,

Related organisations

Leave a Reply

Your email address will not be published. Required fields are marked *